Clinical Trial Update: PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer

View source ↗

Summary

A completed clinical trial investigating biomarkers that predict response or resistance to anti-EGFR therapies in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Vectibix (panitumumab)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Metastatic Colorectal Cancer | Status: COMPLETED